Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
1999 1
2000 4
2001 11
2002 10
2003 9
2004 6
2005 7
2006 11
2007 16
2008 35
2009 23
2010 16
2011 22
2012 23
2013 27
2014 22
2015 15
2016 19
2017 9
2018 6
2019 5
2020 4
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17935269

284 results

Results by year

Filters applied: . Clear all
Page 1
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Robidoux A, et al. Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4. Lancet Oncol. 2013. PMID: 24095300 Clinical Trial.
[New treatment approaches in breast cancer].
Spirig C, Thürlimann B, Huober J. Spirig C, et al. Ther Umsch. 2008 Apr;65(4):207-10. doi: 10.1024/0040-5930.65.4.207. Ther Umsch. 2008. PMID: 18622912 German.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. de Azambuja E, et al. Lancet Oncol. 2014 Sep;15(10):1137-46. doi: 10.1016/S1470-2045(14)70320-1. Epub 2014 Aug 14. Lancet Oncol. 2014. PMID: 25130998 Clinical Trial.
284 results